NCE Discovery

Home > R&D > Technology > NCE Discovery


  • Irreversible potent pan-Her inhibitor
  • Effective and tolerable for Her-2 & EGFR driven cancers
  • Excellent in vivo efficacy in Xenograft model of Her-related cancer cells


  • Selective & Excellent activity to EGFR mutants including T790M
  • No event of diarrhea or rash caused by EGFR WT
  • Clinical trial conducting in advanced NSCLC patients with EGFR mutations


  • Irreversibly designed BTK inhibitor
  • Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLC款
  • Phase 1 clinical study is ongoing in rheumatoid arthritis and scheduled in lymphoma